Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

导出原文传递

翻译打印收藏纠错

作者： Ono,N. ^[1] ; Yamazaki,T. ^[2] ; Nakanishi,Y. ^[3] ; Fujii,T. ^[4] ; Sakata,K. ; Tachibana,Y. ; Suda,A. ; Hada,K. ; Miura,T. ; Sato,S. ; Saitoh,R. ; Nakano,K. ; Tsukuda,T. ; Mio,T. ; Ishii,N. ; Kondoh,O. ; Aoki,Y.

作者单位： Pharmaceutical Research Department 2, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan ^[1] Discovery Platform Technology Department, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan ^[2] Chemistry Research Department 2, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan ^[3] Preclinical Research Department, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan ^[4]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer science

2012年103卷2期

342-349页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

Cancer science

相似文献

Cancer science

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

Cancer science

相似文献

Cancer science

相关期刊

检索历史清除